Nonalcoholic fatty liver disease (NAFLD), or metabolic dysfunction-associated steatotic liver
disease (MASLD), represents the most common cause of chronic liver disease, and its …

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of hepatic disorders that
ranges from excess lipid storage in the liver (hepatosteatosis) to progressive nonalcoholic …

Introduction Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic
liver disease worldwide and closely interconnected to the metabolic syndrome. Liver …

Agonists for thyroid hormone receptor β (TRβ) show promise in preclinical studies and
clinical trials to improve non-alcoholic fatty liver disease. A recent study on human livers …

While the links between metabolic dysfunction associated steatotic liver disease liver
disease (MASLD) and obesity, insulin resistance are widely appreciated, there are a host of …

Nonalcoholic fatty liver disease (NAFLD) is the dominant cause of liver disease worldwide.
Nonalcoholic steatohepatitis (NASH), a more aggressive presentation of NAFLD, is …

Background Thyroid hormone is critical for tissue–organ development, growth,
differentiation, and metabolism. In murine models of advanced nonalcoholic steatohepatitis …

Background and Purpose Activation of hepatic thyroid hormone receptor β (THR‐β) is
associated with systemic lipid lowering, increased bile acid synthesis, and fat oxidation. In …

The recent FDA approval of Rezdiffra (resmetirom), an oral partial agonist of the thyroid
hormone receptor-beta (THR-beta), for the treatment of noncirrhotic non-alcoholic …

The typical modern lifestyle contributes to the development of many metabolic-related
disorders, as exemplified by metabolic syndrome. How to prevent, resolve, or avoid …